SteadyMed Ltd. (STDY) Announces Quarterly Earnings Results, Misses Expectations By $0.01 EPS

SteadyMed Ltd. (NASDAQ:STDY) issued its quarterly earnings data on Friday. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by $0.01, MarketWatch Earnings reports. The company had revenue of $0.32 million during the quarter, compared to analysts’ expectations of $0.26 million. SteadyMed had a negative net margin of 3,759.61% and a negative return on equity of 240.57%.

Shares of SteadyMed (STDY) traded down 1.98% during mid-day trading on Friday, reaching $6.20. 9,027 shares of the company traded hands. The company’s 50 day moving average is $6.35 and its 200 day moving average is $5.58. The stock’s market capitalization is $156.06 million. SteadyMed has a 52-week low of $2.25 and a 52-week high of $9.70.

WARNING: This report was first reported by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this report on another website, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this report can be accessed at

Separately, Zacks Investment Research upgraded shares of SteadyMed from a “sell” rating to a “hold” rating in a report on Tuesday, July 18th.

SteadyMed Company Profile

SteadyMed Ltd. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of various therapeutic product candidates. Its primary focus is to obtain approval in the United States for the sale of Trevyent for the treatment of pulmonary arterial hypertension (PAH).

Earnings History for SteadyMed (NASDAQ:STDY)

Receive News & Ratings for SteadyMed Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SteadyMed Ltd. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply